99 Tc^m-MIBI SPECT/CT同机融合显像对鼻咽癌临床应用的研究进展  

The Research Progress of Clinical Applications of 99 Tc m-MIBI SPECT/CT Fusion Imaging in Nasopharyngeal Carcinoma

作　　者：程立萍 郭林[1] 金刚[1] CHENG Liping;GUO Lin;JIN Gang(Department of Nuclear Medicine,The Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China)

机构地区：[1]哈尔滨医科大学附属第二医院核医学科,黑龙江哈尔滨150086

出　　处：《标记免疫分析与临床》2020年第12期2186-2190,共5页Labeled Immunoassays and Clinical Medicine

基　　金：2015年哈尔滨市应用技术研究与开发项目(99 Tc m-MIBI SPECT/CT肿瘤系列融合显像联合肿瘤标志物的临床应用研究)(编号:2015RAXYJ066)。

摘　　要：近年来,随着SPECT/CT同机融合显像技术的不断发展,99 Tc m-MIBI作为一种非特异性的亲肿瘤显像剂在鼻咽癌的临床应用中发挥着越来越高的价值。本文就99 Tc m-MIBI的显像机制、SPECT/CT同机融合的优势、99 Tc m-MIBI SPECT/CT同机融合显像对鼻咽癌的临床应用价值进行综述。In recent years,with the fast development of SPECT/CT fusion imaging technology,99 Tc m-MIBI,as a non-specific tumor-friendly imaging agent,has been playing a more important role in the clinical application of nasopharyngeal carcinoma.This paper reviewed the imaging mechanism of 99 Tc m-MIBI and the advantages of SPECT/CT co-fusion,also explored the clinical value of 99 Tc m-MIBI SPECT/CT co-fusion imaging in nasopharyngeal carcinoma.

关 键 词：99 Tc m-MIBI SPECT/CT 融合显像 鼻咽癌 临床应用 

分 类 号：R817[医药卫生—影像医学与核医学] R739.6[医药卫生—放射医学]